Join our Community
Support ToI and remove all ads
Learn more
×

Dr. Tal Zaks

A municipal worker cleans swastikas spray painted on columns of the Rivoli Street in central Paris, on October 11, 2020. (Stephane De Sakutin/AFP)
April 7, 2021, 2:57 pm
Pandemic fueled anti-Semitism, with vaccine firm heads likened to Nazis – study
On Holocaust Remembrance Day eve, TAU researchers say that while lockdowns led to drop in physical attacks, conspiracies flourished online about outbreak being Israeli, Jewish plot
By Agencies and ToI Staff
Illustrative: Thabisle Khlatshwayo receives her second shot at a vaccine trial facility for AstraZeneca at Soweto's Chris Sani Baragwanath Hospital outside Johannesburg, South Africa, November 30, 2020. (AP Photo/Jerome Delay)
January 6, 2021, 11:16 pm
Health official: ‘Worrying’ study on vaccine’s potency against S. African strain
Sharon Alroy-Preis says unclear what impact vaccination has on COVID variant, but warns it may offer less protection against mutation
By ToI Staff
University of Miami Miller School of Medicine lab technician processing blood samples from study participants who volunteered to take part in testing the National Institutes of Health-funded Moderna COVID-19 vaccine in Miami, September 2, 2020. (AP Photo/Taimy Alvarez, File)
November 30, 2020, 3:12 pm
Moderna seeks US, EU approval for vaccine as final results show 94% efficacy
‘I allowed myself to cry for the first time’ when learning of the results, says Israeli chief medical officer as pharma firm asks regulators to allow emergency use of the jab
By Agencies and ToI Staff
A syringe and a vial with the logo of US biotech firm Moderna. (AFP)
November 17, 2020, 12:20 am
With new vaccine technology, small biotech firm Moderna battles mighty pandemic
Massachusetts-based company saw share price soar after announcing its coronavirus vaccine is 94.5% effective. Bullish CEO, promising up to a billion doses, says it’s just the start
By AFP and ToI Staff
Moderna's Chief Medical Officer Dr. Tal Zaks. (Screenshot: YouTube)
November 16, 2020, 6:41 pm
Moderna’s top medical officer says Israel will be among first to get vaccine
It’s ‘around the corner,’ says Tal Zaks, who is Israeli, estimating that shots will reach Jewish state early next year
By ToI Staff and Agencies
An entrance to a Moderna, Inc., building, May 18, 2020, in Cambridge, Massachusetts. (AP Photo/Bill Sikes)
May 28, 2020, 3:21 am
Amid virus vaccine hopes, Moderna top execs said to have sold millions in stocks
US biotech firm’s shares soared when it claimed progress in trials; analysts say sales, including by Israeli chief medical officer, are legal but undermine faith in company
By ToI Staff and Agencies
In this March 16, 2020, file photo, a pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, at the Kaiser Permanente Washington Health Research Institute in Seattle. The vaccine by Cambridge, Massachusetts-based Moderna Inc., generated antibodies similar to those seen in people who have recovered from COVID-19 in a study volunteers who were given either a low or medium dose. (AP Photo/Ted S. Warren, File)
May 18, 2020, 9:04 pm
Moderna’s Israeli top medical officer: We’ve shown today that our vaccine works
US biotech firm’s shares soar as it claims tests of first volunteers show its vaccine candidate produces immune response, ‘has potential to prevent COVID-19’; Phase 3 tests in July
By ToI Staff and Agencies
Load More
Sign in or Join The Times of Israel Community
Paying ToI Community members are invited to comment on articles
Please use the following structure: example@domain.com
Or Continue with
By joining you agree to the terms and conditions
Register to continue
Or Continue with
Log in to continue
Sign in or Join The Times of Israel Community
Only ToI Community members can comment below articles
Forgot your password? / Send me a login link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Please use the following structure: example@domain.com
Confirm Mail
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to . Once you're set up, you can start enjoying Community benefits and commenting.
Back to top
Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
image
Register for free
and continue reading
Registering allows you to manage your newsletters and alerts and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure: example@domain.com
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
I forgot my password / Send me a sign in link
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.